Delfa Limited is a limited company specializing in the development of AI-powered solutions for clinical research. Established in 2025, Delfa focuses on streamlining the recruitment and retention of patients within clinical trials, utilizing artificial intelligence to enhance efficiency. The company’s core service revolves around deploying ‘always-on’ AI agents designed to automate patient engagement and data collection. These agents are specifically tailored to the needs of clinical research sites, offering a proactive and personalized experience for participants. Delfa’s primary service offering is the creation and implementation of these AI agents, which leverage natural language processing and machine learning to facilitate patient communication, scheduling, and data entry. The company’s expertise extends to the integration of these agents with existing clinical trial management systems. Delfa’s business model centers around providing a robust and scalable solution, aiming to reduce administrative burden and improve patient adherence within clinical trials. The company’s operations are structured as a limited company, registered with the Securities and Exchange Commission (SIC Code: -62012) and operating from its headquarters at 21 Old Town Hall Apartments, London, SE16 3SA. Delfa Limited is actively seeking international expansion, with a demonstrable commitment to building a global presence.

Delfa Limited is a limited company specializing in the development of AI-powered solutions for clinical research. Established in 2025, Delfa focuses on streamlining the recruitment and retention of patients within clinical trials, utilizing artificial intelligence to enhance efficiency. The company’s core service revolves around deploying ‘always-on’ AI agents designed to automate patient engagement and data collection. These agents are specifically tailored to the needs of clinical research sites, offering a proactive and personalized experience for participants. Delfa’s primary service offering is the creation and implementation of these AI agents, which leverage natural language processing and machine learning to facilitate patient communication, scheduling, and data entry. The company’s expertise extends to the integration of these agents with existing clinical trial management systems. Delfa’s business model centers around providing a robust and scalable solution, aiming to reduce administrative burden and improve patient adherence within clinical trials. The company’s operations are structured as a limited company, registered with the Securities and Exchange Commission (SIC Code: -62012) and operating from its headquarters at 21 Old Town Hall Apartments, London, SE16 3SA. Delfa Limited is actively seeking international expansion, with a demonstrable commitment to building a global presence.